Ionis Pharmaceuticals (NASDAQ: IONS) shares plunged after the biotech halved its 2026 sales forecast for Tryngolza to about $50M, down from $100–$110M, on a slower-than-expected launch — even as Q3 revenue jumped 55% to $243M, beating estimates, and its net loss narrowed to $110M. Dawnzera brought in $37M in the quarter, and Ionis kept its full-year revenue outlook at $875–$900M while pushing break-even back to 2029. #Ionis #IONS #Biotech #Earnings #Stocks #WallStreet
167 Views